Member access

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Burzynski Clinic Presents Over Five Years Survival Data From Phase II Trials of ANP for Inoperable Brain Tumors at the Congress

11/15/2013 | 09:34pm US/Eastern

The Burzynski Clinic (BC) announced today that it made a keynote speaker presentation at the 2nd Annual Congress of Asia-Pacific Academy of Anti-Aging Medicine in Beijing, China. Based on the presentation in Beijing, a total of 401 eligible patients (patients who received over 28 days of treatment) with advanced inoperable brain tumors have been treated with antineoplaston A10 and antineoplastons AS2-1 therapy (ANP) in phase II studies. Most of the patients (87%) were diagnosed with high-grade tumors and the remaining patients were diagnosed with low-grade tumors. The patients were diagnosed by pathologists not associated with BC and objective responses were verified by Central Radiology Review. The group of 77 patients (19%) survived over five years from the treatment start. Of particular interest were results in patients with brainstem gliomas. The group of 17 patients with brainstem glioma underwent the treatment and 65% of these patients survived over five years. An additional group of 42 patients diagnosed with diffuse intrinsic pontine glioma (DIPG) have been treated and a total of 19% survived over five years.

The quality of survival is very good and there is no long-term toxicity related to ANP.

These clinical results are very encouraging, since they describe a positive ANP effect on some of the worst malignancies in the entire oncology field, but they will require FDA approval.

Burzynski Clinic is committed to developing treatments for cancer based on genomic and epigenomic principles.

Forward-looking statements in this release are made pursuant to the safe harbor provisions of the federal securities laws. Information contained in forward-looking statements is based on current expectations and is subject to change, and future events may differ materially from those discussed herein due to a number of factors, including, but not limited to, risks and uncertainties related to the clinic's ability to use Antineoplastons A10 and AS2-1. Burzynski Clinic does not undertake to update any such forward-looking statements or to publicly announce developments or events relating to the matters described herein.

For Burzynski Clinic
Carolyn Powers, 713-335-5664
carolyn@burzynskiclinic.com


© Business Wire 2013
Latest news
Date Title
<1m ago FORCEFIELD ENERGY : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
<1m ago PEPSICO : Logo
<1m ago Top Allergan holder Paulson urges deal with Shire - sources
1m ago MICROSOFT : names new general manager for Oman, Bahrain
1m ago ECOSOC UNITED NATIONS ECONOMIC AND SOCIAL COUNCI : Secretary-General Commends Mozambique on Holding of ‘Generally Peaceful’ Elections
1m ago THE BROE GROUP : Invests in $120 Million Round of Funding for Invitae, a Healthcare Technology Company Creating a Genetic Information Business
1m ago RESEARCH AND MARKETS : Global and Chinese Citric Acid Industry Report 2014-2019
1m ago RESEARCH AND MARKETS : Global and Chinese D-Threonine Industry Report 2014
2m ago Patients treated with radiation therapy who have tumors in left breast have comparable overall survival to those with tumors in the right breast
3m ago NOVARTIS : Health and Human Services Department (HHS); Food and Drug Administration (FDA) (F.R. Page 57941) - Meeting
Latest news
Advertisement
Hot News 
BANCO ESPIRITO SANTO : Novo Banco's Angolan Bank to Lose Most of Loan From Collapsed Banco Espirito Santo
NUTRECO : SHV and Nutreco announce a recommended cash offer of EUR 40 per share for all shares of Nutreco
SINOCOKING COAL AND COKE CHEM IND : Aboveground Syngas Facility Commences Operations
PRESIDENT ENERGY : Oil Discovery in Paraguayan Chaco
NCR : Announces Preliminary Third Quarter 2014 Results and Lowers Full-Year 2014 Guidance
Most Read News
4h ago Lufthansa pilots extend strike to ground long-haul flights
1d agoDJENERGY DEVELOPMENT : Secures $315 Million Financing For Wind Project
6h ago Adidas shares jump on report of bid for Reebok unit
4h ago IBM to pay Globalfoundries $1.5 billion to take chip unit
1d ago MICROSOFT PLANS TO LAUNCH SMARTWATCH WITHIN WEEKS : Forbes
Most recommended articles
<1m ago Top Allergan holder Paulson urges deal with Shire - sources
3m ago Fidelity Contrafund loads up on Facebook and it pays off
3m ago COT : Crude Speculative Long Position at 18 Month Low
7m ago Japanese stocks lead shares worldwide, IBM weighs on Dow
7m ago WALL STREET STOCK EXCHANGE : Japanese stocks lead shares worldwide, IBM weighs on Dow
Dynamic quotes  
ON
| OFF